In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway
IntroductionSeveral diseases caused by the dysregulation of complement activation can be treated with inhibitors of the complement components C5 and/or C3. However, complement is required for serum bactericidal activity (SBA) against encapsulated Gram-negative bacteria. Therefore, C3 and C5 inhibiti...
Main Authors: | Emma Ispasanie, Lukas Muri, Marc Schmid, Anna Schubart, Christine Thorburn, Natasa Zamurovic, Thomas Holbro, Michael Kammüller, Gerd Pluschke |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1180833/full |
Similar Items
-
Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against Haemophilus influenzae type b
by: Lukas Muri, et al.
Published: (2022-12-01) -
Product review on the IMD serogroup B vaccine Bexsero®
by: Ala-Eddine Deghmane, et al.
Published: (2022-01-01) -
A Case of Meningococcal Meningitis Due to W135 Strain
by: Aliye BAŞTUĞ, et al.
Published: (2008-03-01) -
Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy
by: Arianna Neri, et al.
Published: (2022-05-01) -
Epidemiology of Invasive Meningococcal Disease in Colombia: A Retrospective Surveillance Database Analysis
by: Wilfrido Coronell-Rodriguez, et al.
Published: (2023-11-01)